Eli Lilly to partner with Cipla, Lupin, Sun Pharma to manufacture, distribute Baricitinib in India

US drug-maker Eli Lilly, on May 10, announced that it had issued royalty-free, non-exclusive voluntary licenses to established Indian pharmaceutical manufacturers of generic medicines, Cipla, Lupin and Sun Pharmaceutical Industries to manufacture and distribute Baricitinib in India.

Lilly said it was also in discussions with several other Indian manufacturers for the potential grant of additional voluntary licenses.

Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, India for use in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).